Prof. Linzhao Cheng, Ph.D. (Pending)
Prof. Cheng is Edythe Harris Lucas and Clara Lucas Lynn Endowed Chair in Hematology, Professor of Medicine and Oncology, and a founding member and a former co-director of Stem Cell Program in the Johns Hopkins Institute for Cell Engineering, Johns Hopkins University School of Medicine. He is also the Associate Director for Basic Research of the Division of Hematology. He was a recipient of USA Presidential Early Career Award for Scientists and Engineers (PECASE, 2003), and a Fellow of the American Association for the Advancement of Sciences (AAAS). As an overseas Chinese, Prof. Cheng serves as a member in advisory and review panels for initiative on stem cells and regenerative medicine in China, and the President of Chinese Stem Cell Foundation, a non-profit and non-political professional organization registered in CA, USA. With years of industrial experience, he also serves as a member of scientific advisory boards of several biotech companies.
Prof. Kevin Costa
Prof. Costa is Director of the Section of Cardiovascular Cell and Tissue Engineering at the Icahn School of Medicine at Mount Sinai in New York City. Prof. Costa was previously trained at the Johns Hopkins University and on the faculty as Associate Professor of Biomedical Engineering at Columbia University. As a "blue-blood" biomedical engineering (BME) expert (B.S. and M.S. in BME from Boston University, Ph.D. in BME from UC San Diego, and postdoc in BME from JHU and University of Washington) in cell and tissue biomechanics and cardiac tissue engineering, he has developed one of the first engineered cardiac tissue systems. Since 2009, he has been working with Prof. Ronald Li to translate such systems into human cells. Prof. Costa has received research funding from the Whitaker Foundation, the National Science Foundation (NSF) and the National Institutes of Health (NIH; NHLBI, NIBIB, and NIGMS). He was also a recipient of the prestigious Faculty Early Career Development (CAREER) Award from the NSF. Prof. Costa is an inventor of several cardiac tissue engineering technologies and one of the scientific co-founders of Novoheart Hong Kong.
Prof. Roger Hajjar, M.D. (Pending)
Professor Hajjar is an internationally renowned entrepreneurial clinician scientist in the field of cardiac gene therapy for heart failure, and is the Arthur and Janet C. Ross Professor of Medicine at the Mount Sinai School of Medicine. Professor Hajjar graduated with a B.S. in Biomedical Engineering from the Johns Hopkins University, followed by obtaining his M.D. from Harvard-MIT. Before he got recruited to join the Icahn School of Medicine at Mount Sinai in New York as Director of the Cardiovascular Research Center, he was on the faculty of the Harvard Medical School with the last position as Director of the Cardiovascular Laboratory of Integrative Physiology and Imaging. Professor Hajjar is a former chair of the Cardiac Contractility, Hypertrophy, and Failure Study Section of the National Institutes of Health. His numerous distinguished awards include 2012 Dean’s Award for Excellence in Translational Science, Distinguished Alumnus Award of JHU 2011, Doris Duke Clinical Scientist award of 1999, and Young Investigator Award of American Heart Association, 1996. Professor Hajjar’s inventions have led to several start-ups, including Nanocor, Celladon (listed in NASDAQ) and Sumocor. He has also served on the board or as an advisor to multiple biotech companies including Cellectis, Celladon, Nanocor, and L-Nutra.
Prof. Michelle Khine
Prof. Khine, a leading expert in microfluidic platforms, is Director of the Bio-Entrepreneurial Program at UC Irvine and Scientific Co-founder of Novoheart. She received her B.S. and M.S. in Mechanical Engineering from UC Berkeley and Ph.D. in Bioengineering from UC Berkeley and UCSF. Upon graduation, she became an Assistant & Founding Professor at UC Merced. She is currently a Professor of Biomedical Engineering, Chemical Engineering and Materials Science, and the Director of Faculty Innovation, at the Henry Samueli School of Engineering, UC Irvine. As a serial entrepreneur, she was the Scientific Founder of Fluxion Biosciences and Shrink Nanotechnologies, among others. Prof. Khine was named one of Forbes “10 Revolutionaries” in 2009 and by Fast Company Magazine as one of the “100 Most Creative People in Business” in 2011. Prof. Khine has also been recognized as “Top 35 Innovators under 35 in the world” by MIT Technology Review. She was awarded the NIH New Innovator's Award, was named a finalist in the World Technology Awards for Materials, and by Marie-Claire magazine as “Women on Top: Top Scientist”. Prof. Khine has been named a Fellow of the National Academy of Inventors in 2016, and she is also a fellow of the American Institute for Medical and Biological Engineering.
Prof. Ronald Li
Prof. Ronald Li is a co-founder of Novoheart, and has been serving as the CEO since 2016. He is concurrently Director of Ming-Wai Lau Centre for Reparative Medicine, HK node, Karolinska Institutet (KI), Sweden, with a professorial cross appointment at the Dr. Li Dak-Sum Research Centre, The University of Hong Kong (HKU)-KI Collaboration in Regenerative Medicine of HKU. Prof. Li has been an advocate of stem cell technology for many years, starting from his career as Assistant Professor of Cardiology, and Cellular and Molecular Medicine at the Johns Hopkins University (JHU) School of Medicine. He founded and led the Human Embryonic Stem Cell Consortium when he was recruited in 2005 to become a tenured Associate Professor at the University of California, Davis, in light of state’s USD3-billion stem cell initiative Proposition 71. Prof. Li was the Founding Director of the Stem Cell & Regenerative Medicine Consortium (SCRMC) at the University of Hong Kong (HKU) from 2010 to 2015. He also co-directed the Section of Cardiovascular Cell & Tissue Engineering in Icahn School of Medicine at Mount Sinai with Prof. Kevin Costa. Prof. Li has received multiple accolades and recognitions during his career, including the Spirit of Hong Kong Innovating for Good Award by the South China Morning Post (2015), the Top Young Faculty Award (2002, 2004), the Top Prize for the Young Investigator Basic Research (2001) and Top Postdoctoral Fellow Helen Taussig Award (2001) of JHU School of Medicine, Young Investigator Award 1st Prize from the Heart Rhythm Society (2002), and the Career Development Award from the Cardiac Arrhythmias Research & Education Foundation (2001).
Prof. Li graduated with his B.S. with honors in Biotechnology from University of Waterloo, Ontario, on Dean’s List and his Ph.D. in Cardiology/Physiology at the University of Toronto.
Prof. Gordon Tomaselli, M.D, (Pending)
Prof. Tomaselli is the Michel Mirowski M.D. Professor of Cardiology and Professor of Medicine and Cellular and Molecular Medicine at Johns Hopkins University (JHU). He serves as Chief of Cardiology and co-director of the Johns Hopkins Heart and Vascular Institute. He was Immediate Past President of the American Heart Association (AHA), and the Co-Director of the Donald W. Reynolds Cardiovascular Clinical Research Center, which was founded in 2003 with the goal of understanding the causes of sudden cardiac death and developing new therapies. He was also past president of the Cardiac Electrophysiology Society.
Prof. Leslie Tung, Ph.D. (Pending)
Prof. Tung is Professor and Director of the Department of Biomedical Engineering (Ranked #1 in the US) at the Johns Hopkins University School of Medicine. He graduated with his B.S, M.S. and Ph.D. at MIT. His research examines how electrical waves propagate in heart cells grown in a dish as a model system to study mechanisms for cardiac arrhythmias — otherwise known as irregular heartbeats.